Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | ARISTO Aristo Bio-Tech and Lifescience Ltd. Pharma · SME | JFLLIFE JFL Life Sciences Ltd. Pharma · SME | CURIS Curis Lifesciences Ltd. Pharma · SME | ONYX Onyx Biotec Ltd. Pharma · SME |
|---|---|---|---|---|
| Final Score | 74 | 65 | 46 | 15 |
| Verdict | UNDERVALUED | UNDERVALUED | FAIR VALUE | OVERVALUED |
| Style | Top Setup | Deep Value | Deep Value | OVERVALUED |
| Piotroski | 7/9 | 6/9 | 5/9 | 3/9 |
| Valuation | 29/30 | 26/30 | 24/30 | 6/30 |
| Growth | 18/25 | 21/25 | 18/25 | 7/25 |
| Quality | 12/20 | 12/20 | 0/20 | 0/20 |
| Balance Sheet | 10/15 | 9/15 | 9/15 | 9/15 |
| Cash Flow | 8/10 | 1/10 | 0/10 | 0/10 |
| Price | ₹94.3 | ₹9.9 | ₹110 | ₹42 |
| P/E | 9.41 | 10.30 | 16.60 | — |
| P/B | 1.52 | 1.44 | — | 1.41 |
| ROE | 17.60% | 15.00% | — | -0.38% |
| ROCE | 19.50% | 18.20% | — | 1.14% |
| Debt / Equity | 0.78 | 0.48 | 0.00 | 0.27 |
| FCF Yield | 7.40% | — | — | — |
| Dividend Y | 0.50% | — | — | — |
| Altman Z | 3.51 | 2.60 | 0.00 | 2.78 |
| Promoter % | 73.42% | 67.47% | 68.03% | 65.10% |
| Mkt Cap (₹Cr) | 67.60 | 66.00 | 88.90 | 78.00 |
| Graham # | ₹124.6 | ₹12.32 | — | — |
| Fair PE | 42.0 | 42.0 | 42.0 | 23.5 |
| MoS % | +78.7% | +75.7% | +97.5% | — |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startARISTO163
JFLLIFE25
CURIS78
ONYX74